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Introduction
Carbohydrate metabolism disorders of varying na-
ture can also be found in adolescent patients. It is 
known that any impairment of carbohydrate metab-
olism, accompanied by hyperglycemia, regardless of 
etiology, leads to chronic complications. Therefore, 
early recognition of elevated blood glucose levels and 
rapid normalization is very important. The under-
lying causes of hyperglycemia can be very diverse; 
excessive amounts of glucose may also stem from 
conditions other than type 1 diabetes. Currently, 
much attention is devoted to cardiovascular diseases 
underlying hyperglycemia; what is more, these may 
already occur in young patients. The results of many 
studies indicate that the processes leading to the oc-
currence of cardiovascular diseases in patients with 
type 1 diabetes begin already in childhood and ado-
lescence [1, 2]. Long-term studies indicate that in 
children and adolescents who exhibit risk factors, the 
risk of developing macroangiopathy is significantly 
higher than in the general population [3, 4]. Graves 
end Donaghue has recently provided a comprehen-
sive discussion of this issue [5]. The authors believe 
that subclinical cardiovascular diseases may develop 
already in the first decade after diagnosis of type 1 
diabetes. Therefore, blood pressure and dyslipidemia 
screening should be initiated in children from 11 
years of age. In addition, with a family history of hy-
percholesterolemia, screening should be carried out 
as early as 2 years of age. It is assumed that the fre-
quency of cardiovascular risk factors is high in youth 
with type 1 diabetes and is associated with diabetes 
duration, obesity, and metabolic control [6].
Risk factors for microangiopathy 
in diabetic patients  
at developmental age
The recommendations of the International Society 
for Pediatric and Adolescent Diabetes (ISPAD) re-
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garding the prevention of vascular complications in-
dicate the existence of documented risk factors for 
macroangiopathy in children and adolescents. These 
include hyperglycemia, hypertension, and lipid dis-
orders [7, 8]. Other authors add to this list the pres-
ence of a cardiovascular disease and/or lipid disorders 
in the patient’s family [9]. Endothelial dysfunction is 
also important in the development of chronic com-
plications of diabetes with microangiopathy [10]. 
Endothelial progenitor cell (EPC) dysfunction may 
underlie the mechanisms involved in the develop-
ment of vascular complications in diabetic patients 
[11].
Hyperglycemia
Hyperglycemia is a recognized risk factor for the 
development of microangiopathy in type 1 diabetes. 
Inadequate metabolic control of diabetes is also a risk 
factor for macroangiopathy in adult patients with 
type 1 diabetes. The importance of hyperglycemia 
in the development of macroangiopathy in type 1 
diabetes has been confirmed by several publications.
Persistent hyperglycemia leads to:
• the activation of nonenzymatic glycation of pro-
teins — advanced glycation end-products (AGEs) 
become present in vascular walls in the early sta-
dium of diabetes, resulting in their damage;
• the activation of the sorbitol cycle, a side cycle 
of glucose metabolism – an increase in glucose 
concentration in the extracellular compartment 
causes the activation of aldose reductase, which 
converts glucose into sorbitol;
• an increase in oxidative stress – due to chronic 
hyperglycemia.
Chronic hyperglycemia leads to damage to the 
vascular endothelium, which leads to the develop-
ment of atherosclerosis [12]. Glycemic variability in 
the pathogenesis of diabetic cardiovascular compli-
cations is particularly dangerous [13–16]. Another 
component of the atherosclerotic process is the im-
pairment of arteriolar vasodilation and the increased 
stiffness of arterioles. Genetic factors also play an 
important role in the pathogenesis of late complica-
tions of immune-mediated diabetes [17]. It has been 
established that endothelial dysfunction in patients 
with type 1 diabetes is independent in comparison 
with classic risk factors. It may be influenced by the 
haptoglobin (Hp) genotype [18]. Hyperlipidemia is 
an important risk factor for angiopathy. Lipid profile 
changes are risk factors for changes in the cardiovas-
cular system. Lipid disorders are closely associated 
with type 2 diabetes, but they also occur in a sig-
nificant proportion of patients with type 1 diabetes, 
including patients at the development age. As recom-
mended by the International Society for Pediatric 
and Adolescent Diabetes (ISPAD) and the American 
Diabetes Association (ADA), hyperlipidemia screen-
ings should be performed on all adolescents with 
type 1 diabetes [7, 19, 20]. If the family of the sick 
child has cardiovascular disease or hypercholesterol-
emia, or family history is unknown, lipid assessment 
should be carried out from the age of two. Insulin 
resistance is one of the risk factors for changes in the 
cardiovascular system [21, 22]. 
Hypertension
The risk factor for micro- and macroangiopathy in 
diabetes is hypertension. Its development often pre-
cedes the diagnosis of diabetes. Patients with type 
1 diabetes are more likely to have disturbances in 
their diurnal blood pressure variability more often 
than non-diabetic patients, consisting in the lack of 
the night-time drop in arterial pressure, which is, 
physiologically, 15–20% of the daytime pressure. 
In these patients, despite higher blood pressure at 
night, blood pressure measured during the day might 
not deviate from normal values. Diagnosis of dis-
turbances in the circadian blood pressure cycle is 
possible only through 24-hour blood pressure moni-
toring. The risk of vascular complications in a group 
of patients with an abnormal circadian rhythm of 
blood pressure is significantly higher than in those 
with a normal circadian rhythm of blood pressure 
[23–25]. 
Diabetes and the autonomic system  
of the heart
At developmental age, type 1 diabetes mellitus is 
the most common cause of the glucose tolerance 
disorder. Type 1 diabetes causes changes in the au-
tonomic system of the heart. Subclinical autonomic 
neuropathy has already been reported in children. It 
was found that autonomic dysfunction is associated 
both with the duration and an inadequate metabolic 
control of the disease [26]. Sympathetic heart dys-
function in diabetes is caused by metabolic, vascu-
lar, as well as immunological factors. Autoantibodies 
against sympathetic ganglia have been demonstrated 
in patients with type 1 diabetes. These antibodies 
are specific for diabetic cardioneuropathy and occur 
independently of antibodies directed against b cells. 
Antibodies directed against sympathetic post-gangli-
onic neurons cause local damage and deterioration of 
nerve cell function in patients with type 1 diabetes 
[27, 28]. It has been shown that hypertension may be 
the first clinical sign of autonomic neuropathy. The 
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association of the cardiac autonomic neuropathy/
hypertension profile with vascular complications is 
consistent with a deleterious effect on vascular he-
modynamics and structure, additional to the effects 
of hypertension [29–31].
Insulin resistance
Insulin resistance is another causative factor of car-
diovascular complications, mainly macroangiopathy. 
It is found more often in juvenile patients with type 
1 diabetes [32, 33]. 
Diagnostics
With the increase in the frequency of chronic com-
plications in diabetes, more and more importance 
is attached to diagnostic methods to adopt an ap-
propriate therapeutic strategy during the period of 
reversible vascular changes. Endothelial dysfunction 
defined as an abnormal vascular response to endo-
thelium-dependent vasodilators can be assessed by 
non-invasive ultrasound methods, while endothelial 
activation is detected by testing the concentration 
of substances produced by the endothelium in the 
blood serum. Jenkins et al draws attention to the 
need to improve diagnostic methods for measur-
ing arterial intima-media thickness, coronary artery 
calcification and angiography, and other methods 
like intravascular ultrasound and optical coherence 
tomography [34]. The same authors also emphasize 
the need to improve novel clinical, biochemical and 
molecular tests; vascular MRI and molecular imag-
ing.
 Markers of cardiovascular damage
Non-invasive methods of assessing cardiovascular 
damage include:
• flow-mediated dilation indicator (FMD);
• ultrasound assessment of carotid, abdominal and 
femoral arteries — intimal plus medial thickness 
(IMT), and aortic intimal plus medial thickness 
(aIMT);
• echocardiographic tests (assessment of left ven-
tricular systolic and diastolic function, assessment 
of left ventricular mass);
• 24-hour monitoring of cardiac function using the 
Holter method;
• 24-hour ambulatory blood pressure monitoring 
(ABPM);
• assessment of microalbuminuria;
• capillaroscopy;
• electron beam tomography (EBT).
Biochemical markers of endothelial damage are:
• adhesion molecules: intercellular adhesion mol-
ecule 1 (ICAM), vascular cell adhesion molecule 
1 (VCAM), thrombomodulin (TM), integrins, 
selectins;
• inflammatory cytokines: interleukins 1, 2, 6 and 
8 (IL-1, IL-2, IL-6, IL-8), tumor necrosis fac-
tor (TNF), monocyte chemoattractant protein 
1 (MCP-1);
• homocysteine;
• C-reactive protein (CRP).
Changes in biomarker levels indicate the involve-
ment of vascular endothelial dysfunction and inflam-
mation in the development of premature arterial 
stiffening and hypertension in patients with type 1 
diabetes [35]. 
Furthermore, these patients show significantly 
higher concentrations of chosen markers of endo-
thelial dysfunction compared to controls [36, 37]. 
Flow-mediated dilation
Flow-mediated dilation (FMD) assessed in the bra-
chial artery has been shown to correlate with changes 
in coronary endothelial function as well as angio-
graphic studies of these vessels, which has been con-
firmed by autopsy [3, 38].
Intima-media thickness
Intima-media thickness (IMT) is used as indicator 
of early lesions of atherosclerosis. The evaluation 
of IMT in the carotid arteries of patients with type 
1 diabetes has shown a more advanced degree of 
atherosclerosis than healthy controls [39]. Other au-
thors believe that aortic IMT (and, to a lesser degree, 
femoral IMT) is more sensitive than carotid and bra-
chial IMT for detecting early macrovascular changes 
in pediatric type 1 diabetic patients [40].
Left ventricular geometry
Significant changes in left ventricular geometry, dia-
stolic function and energy metabolism in patients 
with type 1 diabetes are all associated with overt 
microvascular complications [41]. The disturbance 
of left ventricular systolic and diastolic parameters is 
a preview of the development of diabetic cardiomy-
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opathy. Left ventricular hypertrophy is thought to 
be a preclinical manifestation of hypertension, and 
a risk factor for cardiovascular complications.
Electron beam tomography  
and single-photon emission  
computed tomography 
Based on electron beam tomography (EBT), the de-
gree of coronary artery calcification — an early mark-
er of cardiovascular disease — can be assessed [42]. 
Coronary calcification is an active process which is 
strongly associated with atherosclerosis. This method 
is useful in examining patients over 30 years of age. 
The single-photon emission computed tomography 
(SPECT) method is for evaluating myocardial perfu-
sion imaging (MPI) [43].
Biochemical markers  
of endothelial damage
As regards biochemical markers of endothelial dam-
age in type 1 diabetes, consideration should be given 
to assessing the lipoprotein profile, coagulation and 
fibrinolysis parameters, homocysteine levels, and 
changes occurring during the activation of endothe-
lial cells. It has been shown that endothelial cells are 
activated and chronic vasculitis occurs many years 
before a symptomatic coronary heart disease [44–47]. 
Conclusions
To conclude, it should be emphasized that children 
with type 1 diabetes may develop subclinical cardio-
vascular complications of both micro- and macroan-
giopathy. Their early diagnosis is very important; 
hence, the recommendation to carry out screening 
tests from ten years of age, and in those who are 
particularly at risk from two years of age. Already 
at the age of ten, such measures as the assessment of 
microalbuminuria and blood pressure, ultrasound of 
arteries, ophthalmological tests, echocardiographic 
tests, and capillaroscopic tests are recommended. For 
specific indications, tests should be performed to 
detect early markers of cardiovascular diseases. Early 
diagnosis of risk factors for complications is impor-
tant in the prevention or deferral of complications in 
patients with type 1 diabetes [48, 49, 50, 51]. Many 
authors emphasize the importance of early identifi-
cation and treatment of cardiovascular disease risk 
factors, as recommended in multiple guidelines [52].
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